Monica Colvin-Adams, MD Assistant Professor of Medicine Advanced Heart Failure and Transplantation University of Minnesota Compassionate Allowances Outreach.

Slides:



Advertisements
Similar presentations
Advance Heart Failure Therapy
Advertisements

Mechanical Support for Acute Cardiogenic Shock
Chronic Disease and Co-morbidity with Hearing Loss
Exercise Stress Electrocardiography
Therapy-Related Cardiac Toxicity in Cancer Patients JEAN-BERNARD DURAND, M.D., FCCP, FACC ASSOCIATE PROFESSOR OF MEDICINE MEDICAL DIRECTOR CARDIOMYOPATHY.
Advanced Heart Failure: My Approach
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
 Heart failure is a complex clinical syndrome Can result from:  structural or functional cardiac disorder  impairs the ability of the ventricle to.
LUNG TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):
الجامعة السورية الخاصة كلية الطب البشري قسم الجراحة Perioperative management of the high-risk surgical patient Dr. M.A.Kubtan, MD - FRCS.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
Effect of Obesity on Kidney Transplantation Reference: Potluri K, Hou S. Obesity in kidney transplant recipients and candidates. Am J Kidney Dis. 2010;56:143–156.
Disability, Frailty and Co-morbidity Gero 302 Jan 2012.
Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.
The Heart and Heart Failure in the Year 2013 Jonathan D. Rich, MD Associate Director, Mechanical Circulatory Support Program Bluhm Cardiovascular Institute.
HEART TRANSPLANTATION Overall ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
Optimizing lung transplant outcomes in the adult and pediatric patient. Cynthia S. Herrington, MD Associate Professor of Surgery Keck School of Medicine.
HEART-LUNG TRANSPLANTATION Overall ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
Cardiovascular Diseases Eric Huang Engineering World Health.
Valvular heart surgery in Rajavithi hospital Dr.WITTAWAT PIBUL Rajavithi Hospital.
Elise Wood Stress Management. Narrowing of the walls of the arteries Excessive plaque build up Disrupts blood flow Potential cardiovascular complications.
Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation? July
SSA Hearing on Compassionate Allowances Janet N Scheel MD November 9,2010.
Medication Adherence in Heart Failure University of Central Florida Tessa Dillon.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Wilson Disease Treatment Failures?
HYPERTENSION The Alabama Department of Public Health’s Hypertension Program.
Dr. Mehdi Reza Emadzadeh Department of cardiology Mashhad University of Medical Science.
Treatment of Heart Failure: Beyond Medical Therapy
New guidelines for CABG
BWGHF Liège Heart transplantation 2008.
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
HEART TRANSPLANTATION Pediatric Recipients JHLT Oct; 32(10):
Stent or Surgery: What is Best for a Woman ? Dr R H Stables Cardiothoracic Centre Liverpool UK.
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
G. Rainey Williams Symposium September 30, 2005 CABG in the Elderly Patient: On or Off pump? A Single Center Experience R. Nathan Grantham, M.D.
Prepared and presented by Mohammad H. Kraizem.  The study of the effects of exercise on the body. E  Clinical Exercise Physiology-Involves the application.
M ORNING R EPORT February 17, R ENAL T RANSPLANTS Most frequent transplant 45% of all pediatric transplants 7% of renal transplants ≤ 17y 3 year.
Depressive Disorders and Cardiovascular Medicine Lawson Wulsin, MD Copyright © World Psychiatric Association.
CR-1 Everolimus Benefit/Risk Assessment Howard J. Eisen, MD Thomas J. Vischer Professor of Medicine Chief, Division of Cardiology Drexel University College.
HEART-LUNG TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):
Clinical Review AbioCor® Implantable Replacement Heart H Julie Swain M.D. Cardiovascular Surgeon Ileana Piña M.D. Heart Failure Cardiologist DRAFT.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):
Advanced Therapies Lee R. Goldberg, MD, MPH Medical Director, Heart Failure and Cardiac Transplant Program University of Pennsylvania.
Haissam A Haddad, MD, FRCPC, FACC University of Ottawa Heart Institute
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
No relevant financial relationships to disclose
Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.
LUNG TRANSPLANTATION Adult Recipients 2014 JHLT Oct; 33(10):
Contemporary Management of Myocardial Ischemia
Can Nurses Assist Older CHF Patients With Self-Care? Sallie A. Alvarez NGR 5800 American Heart Association.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Heart transplantation (HTx) provides satisfactory long-term survival for patients with severe cardiomyopathy due to a variety of causes. Despite considerable.
Preemptive Kidney Transplant (PKT) – the Optimal Therapy in ESRD Reference: Connie L. Davis. Preemptive transplantation and the transplant first initiative.
Cardiac Rehabilitation Part I
Bonnie Ky, MD, MSCE Assistant Professor of Medicine and Epidemiology
Heart Transplantation
Soul Mate Real Time, Non-Invasive Heart Data
Graft Dysfunction after Heart Transplantation
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
HEART FAILURE: PATHOPHYSIOLOGY and Diagnosis
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Presentation transcript:

Monica Colvin-Adams, MD Assistant Professor of Medicine Advanced Heart Failure and Transplantation University of Minnesota Compassionate Allowances Outreach Hearing on Cardiovascular Diseases and Multi-organ Transplantation

 5.8 million people in US in 2006  23 million worldwide  One year mortality up to 50% in advanced heart failure  At 40 years old, life-time risk is 1/5  Aging population  Improved treatment of cardiovascular disease Lloyd-Jones, D, Adams, RJ, Brown, TM, et al. Heart disease and stroke statistics update: a report from the American Heart Association. Circulation 2010; Clinical epidemiology of heart failure: public and private health burden.AUMcMurray JJ; Petrie MC; Murdoch DR; Davie APSOEur Heart J Dec

 When symptoms become excessive despite optimal medical therapy  Class III/IV heart failure  Symptoms with minimal activity or at rest  Frequent hospitalizations  Hemodynamic instability  Low cardiac output  Fluid retention  Arrhythmias  Intractable angina

 Chronic Functional Impairment  Angina  Co-morbid conditions  Cachexia  Frequent/prolonged hospitalizations  Mechanical circulatory support

 Persistent functional impairment related to longstanding heart failure, prior surgeries, steroids  Multiple clinic visits  Delayed healing due to multiple sternotomies, medications  Infection  Rejection

 At least 14 clinic visits  biopsies  Cardiac rehabilitation  Early morbidity  Rejection 30% (ISHLT)  Infection 60% (CTRD)  Re-hospitalizations

ISHLT 2009

 Analyzes gene expression data  Identifies gene expression patterns in peripheral blood assoc. with acute cellular rejection  Translates complex signals into a score  2 months post-transplant

Mild Severe Cardiac biopsy is used to monitor for rejection and guide usage of immunosuppressive drugs Most US centers do biopsies in year 1, 2-4 in years 2-5

Most Common Causes of Late Death Malignancy Graft failure Cardiac allograft vasculopathy (coronary artery disease) Morbidity 1 year ( ) 10 years ( ) Hypertension7698% Diabetes2737% Renal Dysfunction 2714% Chronic Dialysis ----5% Kidney Transplant ----1% Abnormal Lipids 7493% Cardiac Allograft Vasculopathy 52% ISHLT 2009 Post Transplant Morbidity

ISHLT 2009

 Reduced and does not return to “normal” after transplant  57% of patients still at NYHA class II-IV  Altered physiologic response of denervated heart to exercise  Glucocorticoids (steroids)  Deconditioning prior to transplant  Effect of heart failure on skeletal muscle Niset G, Hermans L, Depelcin P. Exercise and Heart Transplantation: a review. Sports Med 1991;12:

 Arbitrary  Depends on type of job  Exposure  Functional limitations/Cardiac rehabilitation  Ability to maintain coverage  Economic and social stability

ISHLT 2009

 Advanced heart failure is associated with severe functional and even cognitive limitations  Heart transplantation is a “cure” for heart failure which offers a significant improvement in functional status and return to near-normal levels of functioning in most people  Heart transplantation represents a new medical condition  Due to associated co-morbidities, baseline functional impairment, and complications of transplant, transient and chronic disabilities can ensue at any time during transplant

 Modulation of donor/recipient interaction  Improved therapy for rejection  Earlier detection of rejection and coronary disease  Earlier implantation of LVADs/smaller devices  Less reliance on transplantation Mechanical Circulatory Support